Blueprint Medicines Co. (NASDAQ:BPMC) Shares Bought by Emerald Advisers LLC

Emerald Advisers LLC increased its position in Blueprint Medicines Co. (NASDAQ:BPMC) by 10.2% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 375,866 shares of the biotechnology company’s stock after acquiring an additional 34,666 shares during the period. Blueprint Medicines makes up 1.4% of Emerald Advisers LLC’s portfolio, making the stock its 18th biggest position. Emerald Advisers LLC owned approximately 0.60% of Blueprint Medicines worth $34,768,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Blueprint Medicines in the first quarter valued at approximately $474,000. Hsbc Holdings PLC acquired a new stake in Blueprint Medicines in the 2nd quarter valued at approximately $1,060,000. Comerica Bank boosted its position in Blueprint Medicines by 2,582.9% during the 1st quarter. Comerica Bank now owns 10,839 shares of the biotechnology company’s stock worth $1,028,000 after acquiring an additional 10,435 shares during the period. Federated Hermes Inc. grew its stake in shares of Blueprint Medicines by 27.8% in the second quarter. Federated Hermes Inc. now owns 62,354 shares of the biotechnology company’s stock worth $6,721,000 after purchasing an additional 13,579 shares in the last quarter. Finally, SG Americas Securities LLC increased its holdings in shares of Blueprint Medicines by 82.8% during the second quarter. SG Americas Securities LLC now owns 21,684 shares of the biotechnology company’s stock valued at $2,337,000 after purchasing an additional 9,819 shares during the period.

Blueprint Medicines Stock Performance

NASDAQ:BPMC traded up $3.19 during midday trading on Friday, reaching $90.70. The stock had a trading volume of 619,676 shares, compared to its average volume of 694,702. The stock has a market capitalization of $5.75 billion, a P/E ratio of -42.99 and a beta of 0.58. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.71 and a quick ratio of 3.65. Blueprint Medicines Co. has a 1-year low of $56.74 and a 1-year high of $121.90. The firm’s fifty day simple moving average is $88.79 and its 200-day simple moving average is $98.39.

Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.89) EPS for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.08. Blueprint Medicines had a negative return on equity of 118.86% and a negative net margin of 29.48%. The business had revenue of $128.20 million for the quarter, compared to analyst estimates of $127.56 million. During the same period in the previous year, the company posted ($2.20) earnings per share. The firm’s revenue for the quarter was up 126.5% on a year-over-year basis. On average, equities research analysts forecast that Blueprint Medicines Co. will post -3.82 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

BPMC has been the subject of several research analyst reports. Oppenheimer upped their price objective on shares of Blueprint Medicines from $114.00 to $125.00 and gave the stock an “outperform” rating in a report on Monday, July 8th. Robert W. Baird increased their price objective on shares of Blueprint Medicines from $112.00 to $127.00 and gave the company an “outperform” rating in a report on Friday, August 2nd. UBS Group assumed coverage on shares of Blueprint Medicines in a research note on Thursday, October 24th. They set a “neutral” rating and a $88.00 price objective on the stock. Needham & Company LLC restated a “buy” rating and issued a $133.00 target price on shares of Blueprint Medicines in a research report on Wednesday. Finally, Wells Fargo & Company lowered their price target on Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating on the stock in a research report on Thursday. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $120.39.

Insiders Place Their Bets

In other news, insider Philina Lee sold 41,913 shares of the stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $93.19, for a total value of $3,905,872.47. Following the completion of the sale, the insider now directly owns 34,729 shares of the company’s stock, valued at approximately $3,236,395.51. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, insider Fouad Namouni sold 3,633 shares of the business’s stock in a transaction dated Thursday, October 3rd. The stock was sold at an average price of $89.32, for a total transaction of $324,499.56. Following the transaction, the insider now directly owns 69,070 shares in the company, valued at $6,169,332.40. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Philina Lee sold 41,913 shares of the firm’s stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $93.19, for a total value of $3,905,872.47. Following the completion of the sale, the insider now owns 34,729 shares of the company’s stock, valued at $3,236,395.51. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 4.21% of the company’s stock.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.